UY31162A1 - Espiroindolinas como moduladores de receptores de quimioquinas - Google Patents

Espiroindolinas como moduladores de receptores de quimioquinas

Info

Publication number
UY31162A1
UY31162A1 UY31162A UY31162A UY31162A1 UY 31162 A1 UY31162 A1 UY 31162A1 UY 31162 A UY31162 A UY 31162A UY 31162 A UY31162 A UY 31162A UY 31162 A1 UY31162 A1 UY 31162A1
Authority
UY
Uruguay
Prior art keywords
chemiokin
spiroindolines
receptors modulators
modulators
receptors
Prior art date
Application number
UY31162A
Other languages
English (en)
Inventor
Jing Zhang
Gren Z Wang
Andrew Q Viet
Clark A Sehon
Tamara Ann Miskowski
Nathan A Miller
Ronggang Liu
Terry Vincent Hughes
Pamela A Haile
Dimitar B Gotchev
Krista B Goodman
Ryan Michael Fox
Hilary Schenck Eidam
Brian W Budzik
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY31162A1 publication Critical patent/UY31162A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a un compuesto de la siguiente formula: en la que R1-R6, R10, Y, n, m, p y q son como se definen en esta memoria. Los compuestos y las composiciones de la presente invencion son utiles para el tratamiento de enfermedades asociadas con la sobreexpresion de CCR2.
UY31162A 2007-06-20 2008-06-18 Espiroindolinas como moduladores de receptores de quimioquinas UY31162A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94514707P 2007-06-20 2007-06-20
US4315608P 2008-04-08 2008-04-08

Publications (1)

Publication Number Publication Date
UY31162A1 true UY31162A1 (es) 2008-11-28

Family

ID=40137143

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31162A UY31162A1 (es) 2007-06-20 2008-06-18 Espiroindolinas como moduladores de receptores de quimioquinas

Country Status (9)

Country Link
US (2) US8431590B2 (es)
EP (1) EP2166848A4 (es)
JP (1) JP5341076B2 (es)
AR (1) AR067056A1 (es)
CL (1) CL2008001810A1 (es)
PE (1) PE20090829A1 (es)
TW (1) TW200904423A (es)
UY (1) UY31162A1 (es)
WO (1) WO2008157741A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015708B (zh) 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US20110230660A1 (en) * 2008-12-04 2011-09-22 Method for Preparing a Spiroindoline Method for preparing a spiroindoline and a precursor thereof
WO2010093578A1 (en) * 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
WO2010099098A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Stereoselective hydrogenation of a ketone
EP2531506B1 (en) 2010-02-05 2014-05-14 Intervet International B.V. Spiroindoline compounds for use as anthelminthics
WO2013017678A1 (en) 2011-08-04 2013-02-07 Intervet International B.V. Novel spiroindoline compounds
CN110085302A (zh) * 2012-01-27 2019-08-02 皇家飞利浦有限公司 医学选择系统
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
WO2018134731A1 (en) 2017-01-17 2018-07-26 Glaxosmithkline Intellectual Property Development Limited Non peptidic heterobivalent molecules for treating inflammatory diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025605A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998031364A1 (en) * 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
JP2001278886A (ja) * 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
GB0107907D0 (en) * 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
WO2004041279A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
CA2546147A1 (en) * 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
BRPI0516166A (pt) 2004-09-28 2008-08-26 Janssen Pharmaceutica Nv antagonista do ccr2 de dipiperidina substituìda
EP1890696A4 (en) 2005-06-02 2010-05-05 Janssen Pharmaceutica Nv Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives
WO2007130712A1 (en) * 2006-01-31 2007-11-15 Janssen Pharmaceutica, Nv Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases
EP2190286A4 (en) 2007-08-14 2011-06-01 Glaxo Group Ltd SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS
EP2211618A1 (en) 2007-10-11 2010-08-04 Glaxo Group Limited Piperidinylhydroxyethylpiperidines as modulators of chemokine receptors
WO2009061881A1 (en) 2007-11-07 2009-05-14 Glaxo Group Limited Spirodihydrobenzofurans as modulators of chemokine receptors
MX2010014501A (es) * 2008-06-23 2011-02-25 Janssen Pharmaceutica Nv Antagonistas de piperidil acrilamida de receptor 2 de citocina quimioatrayente.

Also Published As

Publication number Publication date
US20110034499A1 (en) 2011-02-10
US7723350B2 (en) 2010-05-25
JP5341076B2 (ja) 2013-11-13
JP2010530886A (ja) 2010-09-16
CL2008001810A1 (es) 2008-12-26
EP2166848A4 (en) 2011-08-03
AR067056A1 (es) 2009-09-30
WO2008157741A1 (en) 2008-12-24
US20080318990A1 (en) 2008-12-25
TW200904423A (en) 2009-02-01
EP2166848A1 (en) 2010-03-31
US8431590B2 (en) 2013-04-30
PE20090829A1 (es) 2009-07-25

Similar Documents

Publication Publication Date Title
UY31162A1 (es) Espiroindolinas como moduladores de receptores de quimioquinas
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
ECSP12011815A (es) Métodos sintéticos para compuestos espiro-oxoindol
HN2007015177A (es) Derivados de triazolopirazina
SV2011003831A (es) Compuestos organicos
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CO6351738A2 (es) Compuestos organicos
UY31026A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
CR11183A (es) Espirociclos como inhibidores de la 11-beta hidroxiesteroide deshidrogenasa de tipo 1
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CO6680683A2 (es) Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias
CO6351724A2 (es) Inhibidores de cmet
CR11491A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP066991A (es) 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas
CR10948A (es) Compuestos triciclicos, composiciones y procedimientos
ECSP11011244A (es) Nuevos herbicidas.
GT200500311A (es) Compuestos organicos
BRPI0821102A2 (pt) Preparação de derivados de di-hidropirrol como intermediários
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida
CR8669A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
SV2009003253A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
UY32748A (es) 2-carboxamida-cicloamino-ureas